If there is a suitable donor, HSCT is the treatment of choice for WASP-positive patients with XLT because of their high frequency of complications, including intracranial hemorrhage, autoimmune diseases and IgA nephropathy. 3 Two-thirds of WASP-positive patients with splice-site mutations exhibit XLT and show the highest incidence of lymphomas, particularly for intron 6 splice-site mutations. 4 We reported earlier several members of a single family diagnosed with XLT. 5 Briefly, the present patient was a 9-year-old boy with a history of severe cranial hematoma at birth and purpura at the age of 2 months. He had no history of eczema, severe infection or autoimmune disease. Platelet count was 19 Â 10 9 /l with small platelets (mean platelet volume [MPV]: 4.8 fl) at age 9 years. Direct sequencing of the WASP gene revealed a splice-site G-to-A mutation at position þ 5 in intron 6. WASP expression levels in the patient were one-third those in the normal control, and the mother was a heterozygous carrier of the same mutation. His sister was diagnosed as a heterozygous symptomatic carrier of XLT at age 6 years, and her maternally derived X-chromosome was randomly inactivated. 5 Her platelet counts increased gradually from 39 Â 10 9 /l with low MPV at diagnosis to 80 Â 10 9 /l with normal MPV at age 15 years, which suggested a proliferation/survival advantage in cells with active chromosomes bearing normal WASP or spontaneous in vivo reversion of the WASP mutation would develop. 6 He received HSCT with non-manipulated bone marrow from the 15-year-old sister, whose platelet count was 80 Â 10 9 /l with normal MPV and who was the only HLA-identical individual in the patient's family. The donor and recipient lymphocyte subsets and in vitro lymphocyte proliferation in response to mitogens (phytohemagglutinin and concanavalin A) were normal at the time of HSCT. The conditioning regimen consisted of oral busulfan 1 mg/kg Â 16 doses over 4 days, followed by intravenous cyclophosphamide 50 mg/kg/day for 4 days. Busulfan achieved a steady-state concentration of 680 ng/ml. Clonazepam and mesna were used for prophylaxis against convulsion and hemorrhagic cystitis, respectively, during conditioning. GVHD prophylaxis was short-term methotrexate administered intravenously at a dose of 15 mg/m 2 on day 1 and 10 mg/m 2 on days 3, 6 and 11, and cyclosporine A until day þ 97. G-CSF was used from days þ 5 to þ 17. Hematopoietic reconstitution was rapid, with an absolute neutrophil count of 40.5 Â 10 9 /l on day þ 14 and platelet engraftment was achieved on day þ 16. Complete donor chimerism of bone marrow cells was maintained from day 21 over the 24 months according to fluorescence in situ hybridization. He did not develop acute or chronic graft-versus-host disease, regimen-related complications or infection peri-HSCT. At 24 months after HSCT, lymphocyte subsets and in vitro lymphocyte proliferation in response to mitogens were normal, although platelet counts remained at 40 Â 10 9 /l with normal MPV; these were approximately half the platelet counts in the donor.
We used two-color flow cytometry (FCM)-WASP to serially detect WASP expression in the recipient and donor before and after HSCT (Figure 1 þ cells was lower in the recipient, but remained present. Over time, the recipient has begun to show a similar pattern to that of the donor and now has WASP bright cell populations that were absent before HSCT.
The X-chromosome inactivation patterns of CD3 þ , CD19 þ and CD56 þ cells in the donor and recipient were investigated by methylation-specific polymerase chain reaction assay, which was performed using the human androgen receptor (HUMARA) locus involving a methylation-specific polymerase chain reaction technique, as described earlier. 9 The donor was found to be heterozygous at the HUMARA locus and showed a random pattern that was consistent with those reported earlier, 5 indicating a smaller allele (X1) and lager allele (X2) carrying the mutated WASP and normal WASP, respectively. The recipient at 24 months after HSCT showed a random inactive X-chromosome pattern and the ratio of inactive X1 to X2 in CD3 þ cells was approaching that in the donor, þ and CD56 þ cells obtained by FCM-WASP. On the basis of these results, we speculate that all lymphocyte lineages in the patient will slowly develop into the same pattern as the donor, who showed a predominantly WASP bright population due to the proliferation/survival advantage of the cells with normal WASP.
Long-term follow-up after HSCT is required to assess the clinical course of the patient by FCM-WASP and methylation-specific polymerase chain reaction. It is important to observe how long the acquired random X-inactivation by HSCT will be maintained in this patient. X-chromosome inactivation using HUMARA gene by methylation-specific polymerase chain reaction (M-PCR). Peaks on M-PCR assay of lymphocyte subpopulations show X-inactivation in the patient at 24 months after HSCT (upper panel) and the donor (lower panel). X1 allele and X2 allele refer to X-chromosomes carrying mutated WASP and normal WASP, respectively. Peak ratio numbers indicate the X-inactivation ratios of X1 and X2, respectively.
